AIM
MCRB icon

ARK Investment Management’s Seres Therapeutics MCRB Stock Holding History

ARK Investment Management’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-485,658
Closed -$232M – 308
2021
Q2 		$232M Sell
485,658
-107,139
-18% -$45.2M 0.43% 57
2021
Q1 		$244M Sell
592,797
-94,266
-14% -$43.4M 0.48% 56
2020
Q4 		$337M Buy
687,063
+72,411
+12% +$42.4M 0.9% 36
2020
Q3 		$348M Sell
614,652
-9,295
-1% -$3.09M 2.06% 13
2020
Q2 		$59.4M Buy
623,947
+191,581
+44% +$16.8M 0.64% 34
2020
Q1 		$30.9M Buy
432,366
+68,674
+19% +$4.61M 0.77% 31
2019
Q4 		$25.1M Buy
363,692
+9,944
+3% +$737K 0.63% 36
2019
Q3 		$28.4M Buy
353,748
+1,804
+0.5% +$119K 0.62% 40
2019
Q2 		$22.7M Buy
351,944
+87,558
+33% +$8.31M 0.57% 37
2019
Q1 		$36.3M Buy
264,386
+58,412
+28% +$7.12M 1.04% 29
2018
Q4 		$18.6M Buy
205,974
+3,937
+2% +$551K 0.76% 30
2018
Q3 		$30.7M Buy
202,037
+38,716
+24% +$6.26M 0.93% 36
2018
Q2 		$28.1M Buy
163,321
+42,985
+36% +$7.02M 1.03% 35
2018
Q1 		$17.7M Buy
120,336
+39,061
+48% +$7.49M 0.88% 39
2017
Q4 		$16.5M Buy
81,275
+36,629
+82% +$7.53M 1.31% 35
2017
Q3 		$14.3M Buy
44,646
+6,386
+17% +$1.75M 1.75% 22
2017
Q2 		$8.65M Buy
38,260
+6,764
+21% +$1.39M 1.68% 24
2017
Q1 		$7.1M Buy
31,496
+6,893
+28% +$1.4M 2.05% 17
2016
Q4 		$4.87M Buy
+24,603
New +$5.37M 1.77% 18

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ARK Investment Management's MCRB Position: Q3 2021 in Review

ARK Investment Management sold out of Seres Therapeutics (MCRB) in Q3 2021, closing a stake of 485,658 shares — an estimated $232M sold.

ARK Investment Management first reported a position in MCRB in Q4 2016 and held it in 19 quarters. The position peaked at $348M in Q3 2020. 133 funds tracked by Wall St. Rank hold MCRB as of Q3 2021.

  • ARK Investment Management reported no remaining Seres Therapeutics position as of Q3 2021 after selling out during the quarter.
  • ARK Investment Management sold 485,658 Seres Therapeutics shares in Q3 2021, an estimated $232M.
  • ARK Investment Management first reported a position in Seres Therapeutics in Q4 2016 and held it in 19 quarters.
  • ARK Investment Management's Seres Therapeutics position peaked at $348M in Q3 2020.
  • 133 funds tracked by Wall St. Rank held Seres Therapeutics as of Q3 2021.

Based on ARK Investment Management's 13F filing for Q3 2021, filed 12 Nov 2021.